Vantage logo

Biotech’s near-term key catalysts

Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.

Vantage logo

T3D puts a bet on Alzheibetes

An unusual update at last month’s AAIC meeting puts the focus on a phase 2 readout next year, but time might be running out.

Vantage logo

Medtech takes on pain

Attempts to treat pain with non-opioid drugs have ended in repeated failures – but device makers have met with greater success.